Zusammenfassung
Patientinnen mit Antiphospholipidsyndrom (APS) haben eine gesteigerte Rate an Schwangerschaftskomplikationen. Neben Wachstumsretardierung der Frucht, Frühgeburten und einer gesteigerten Gestoseneigung kommt es insbesondere im 2. und 3. Trimenon häufig zu Aborten. Wie auch bei anderen klinischen Manifestationen des APS sind hierfür Gefäßverschlüsse verantwortlich, die zu plazentaren Infarkten und damit zur Minderperfusion der Frucht führen. Da eine Antikoagulation mit Thrombocytenaggregationshemmern und Heparin in der Lage zu sein scheint, die plazentare Durchblutung zu verbessern, ist das Erkennen gefährdeter Patientinnen, deren Beratung, Behandlung und engmaschige Überwachung in der Schwangerschaft Voraussetzung, um mehr dieser Hochrisikoschwangerschaften erfolgreich zu Ende zu führen. Zur Vermeidung postpartaler Komplikationen beim APS (Thrombosen im Wochenbett, HELLP-Syndrom) ist auch nach der Entbindung eine Antikoagulation und genaue Überwachung zu empfehlen. Abraten wird man von einer Schwangerschaft daher bei APS-Patientinnen inzwischen nur bei aktiver Grunderkrankung (SLE), insbesondere bei Nierenbeteiligung, schlecht einstellbarer Hypertonie und bei schweren zentralnervösen Komplikationen in der Vorgeschichte.
Abstracts
Female patients with antiphospholipid syndrome (APS) suffer from an increased rate of pregnancy complications. Not only is the growth of the fetus retarded; there is also a tendency to premature birth and an increased tendency to gestosis. In particular, abortions are frequent in the second or third trimenon. Vascular occlusions are responsible for these and other clinical manifestations of APS, resulting in placental infarctions and hence deficient perfusion of the fetus. For a successful management of a greater proportion of these high-risk pregnancies it is essential to recognise such risks at an early date and to advise and treat the patients, for it appears that anticoagulation with thrombocyte aggregation inhibitors and heparin can improve the placental blood flow. Even after birth we recommend anticoagulation and close follow-up to avoid postpartal complications in APS (thromboses during childbed, HELLP syndrome). Hence, we would now discourage pregnancy in APS patients only in case of an active underlying disease (SLE), especially with kidney involvement, maladjustable hypertonia and severe central nervous complications in the patient’s previous history.
-
1
Conley C L, Hartmann R C.
A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated LE.
J Clin Invest.
1952;
31
621-62
-
2
Margolius A J, Jackson D P, Ratnoff O D.
Circulating anticoagulants: a study of 40 cases and a review of the literature.
Medicine.
1961;
40
145-202
-
3
Bowie E JW, Thompson J H, Pascuzzi C A. et al .
Thrombosis in SLE despite circulating anticoagulants.
J Lab Clin Med.
1963;
9
416-430
-
4 Feinstein D J, Rapaport S J. Acquired inhibitors of blood coagulation. Spaet TN Prog Haemostas Thromb (1st Edition) New York; Grune and Stratton 1972: 75-95
-
5
Lechner K.
Acquired inhibitors in non-hemophilic patients.
Haemostasis.
1974;
3
65-93
-
6
Thiagarajan P, Shapiro S S, DeMarco L.
Monoclonal immunoglobulin M coagulation inhibitor with phospholipid specifity.
J Clin Invest.
1980;
66
397-405
-
7
Harris E N, Gharavi A E, Boey M L. et al .
Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in SLE.
Lancet.
1983;
II
1211-1214
-
8
Harris E N, Gharavi A E, Hughes G RV.
Anti-phospholipid antibodies.
Clin Rheum Dis.
1985;
11
591-609
-
9
Harris E N, Asherson R A, Gharavi A E. et al .
Thrombocytopenia in SLE and related autoimmune disorders: association with anticardiolipin antibody.
Br J Haematol.
1985;
59
227-230
-
10
Hughes G RV.
The anticardiolipin syndrome.
Clin Exp Rheumatol.
1985;
3
285-286
-
11
Harris E N.
Syndrome of the black swan.
Br J Rheumatol.
1987;
26
324-332
-
12 http: //www.nlm.nih.gov/cgi/mesh/2003/MB_cgi#TreeC20.111.197.
-
13
Alarcon-Segovia D, Deleze M, Oria C V. et al .
Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus. A prospective analysis of 500 consecutive patients.
Medicine.
1989;
68
353-356
-
14
The antiphospholipid antibodies in stroke study group .
Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia.
Stroke.
1990;
21
1268-1273
-
15
Brey R L, Hart R G, Sherman D G. et al .
Antiphospholipid antibodies and cerebral ischemia in young people.
Neurology.
1990;
40
1190-1196
-
16
Hughes G RV.
The antiphospholipid syndrome: ten years on.
Lancet.
1993;
342
341-344
-
17
Wilcox A J, Weinberg C R, o’Connor J F. et al .
Incidence of early loss of pregnancy.
N Engl J Med.
1988;
319
189-194
-
18
Miller J F, Williamson E, Glue J. et al .
Fetal loss after implantation: a prospective study.
Lancet.
1980;
ii
554-556
-
19
Edmonds D K, Lindsay K S, Miller J F. et al .
Early embryonic mortality in woman.
Fertil Steril.
1982;
38
447-453
-
20
Samueloff A, Xenakis E M, Berkus M D. et al .
Recurrent stillbirth. Significance and characteristics.
J Reprod Med.
1993;
38 (11)
883-886
-
21
Oyen N, Skjaerven R, Irgens L M.
Population-based recurrence risk of sudden infant death syndrome compared with other infant and fetal deaths.
Am J Epidemiol.
1996;
144
300-305
-
22
Stern J J, Dorfmann A D, Gutierrez-Najar A J. et al .
Frequency of abnormal karyotypes among abortuses from women with and without a history of recurrent spontaneous abortion.
Fertil Steril.
1996;
65 (2)
250-253
-
23
Nilsson I M, Astedt B, Hedner U. et al .
Intrauterine death and the circulating anticoagulant.
Acta M S.
1975;
197
153-159
-
24
Lubbe W F, Butler W S, Palmer S J. et al .
Lupus anticoagulant in pregnancy.
B J Obst Gyn.
1984;
91
357-363
-
25
Ramsey-Goldman R, Kutzer J E, Kuller L H. et al .
Pregnancy outcome and anti-cardiolipin antibody in women with systemic lupus erythematosus.
Am J Epidemiol.
1993;
138
1057-1069
-
26
Branch D W.
Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome.
Lupus.
1994;
3
275-280
-
27
Love P E, Santoro S A.
Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in SLE and in non-SLE disorders.
Ann Intern Med.
1990;
112
682-698
-
28
Wilson W A, Gharavi A E, Koike T. et al .
International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Report of an international workshop.
Arthritis Rheum.
1999;
42
1309-1311
-
29
Branch D W, Silver R M.
Criteria for antiphospholipid syndrome: early fetal loss, or recurrent pregnancy loss.
Lupus.
1996;
5
409-413
-
30
Loizou S, Byron M A, Englert H J. et al .
Association of quantitative anticardiolipin antibody levels with fetal loss and time of loss in SLE.
Q J Med.
1988;
255
525-531
-
31
Finazzi G, Brancaccio V, Moia M. et al .
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the italian registry.
Am J Med.
1996;
100
530-536
-
32
Infante-Rivard C, David M, Gauthier R. et al .
Lupus anticoagulants, anticardiolipin antibodies, and fetal loss - A case-control study.
N Engl J Med.
1991;
325
1063-1066
-
33
Howard M A, Firkin B G, Healy D L. et al .
Lupus anticoagulant in women with multiple spontaneous miscarriage.
Am J Haematol.
1987;
26
175-178
-
34
Oshiro B T. et al .
Antiphospholipid antibodies and fetal deaths.
Obstet Gynecol.
1996;
87
489-493
-
35 Specker C. Assoziation der aCL zu klinischen Komplikationen. Das Antiphospholipidsyndrom - Bedeutung der Antiphospholipid-Antikörper für Diagnose, Differenzialdiagnose, Prognose und Therapie des systemischen Lupus Erythematodes (Habilitationsschrift, Kap. 3.1.4) Aachen; Shaker Verlag 2002: 34-37
-
36
Specker C, Rademacher J, Söhngen D. et al .
Cerebral microemboli in patients with antiphospholipid syndrome.
Lupus.
1997;
6
638-644
-
37
Silver R M, Porter T F, van Leeuwen I. et al .
Anticardiolipin antibodies: clinical consequences of “low titers”.
Obstet Gynecol.
1996;
89
549-655
-
38 Porter T F, Silver R M, Branch D W. Pregnancy loss and antiphospholipid antibodies. Khamashta MA Hughes Syndrome - Antiphospholipid Syndrome London; Springer 2000: 179-194
-
39 Specker C. Assoziation der aPL zu klinischen Komplikationen. Das Antiphospholipidsyndrom - Bedeutung der Antiphospholipid-Antikörper für Diagnose, Differenzialdiagnose, Prognose und Therapie des systemischen Lupus Erythematodes (Habilitationsschrift, Kap. 4.5) Aachen; Shaker Verlag 2002: 64-72
-
40
Sammaritano L R, Gharavi A E.
Antiphospholipid antibodies and placental anticoagulant protein I.
Lupus.
1994;
3
263-265
-
41
Branch D W, Dudley D J, Mitchell M D. et al .
Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss.
Am J Obstet Gynecol.
1990;
163
210-216
-
42
Rand J H, Xiao-Xuan W, Andree H AM. et al .
Pregnancy loss in the antiphospholipid syndrome - a possible thombogenic mechanism.
N Engl J Med.
1997;
337
154-160
-
43
Lubbe W F, Butler W S, Palmer S J. et al .
Fetal survival after prednisone suppression of maternal lupus-anticoagulant.
Lancet.
1983;
18 (1)
1361-1363
-
44
Cowchock S, Reece E A.
Do low-risk pregnant women with antiphospholipid antibodies need to be treated? Organizing Group of the Antiphospholipid Antibody Treatment Trial.
Am J Obstet Gynecol.
1997;
176
1099-1100
-
45
Kutteh W H.
Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone.
Am J Obstet Gynecol.
1996;
174
1584-1589
-
46
Rai R S, Regan L, Dave M. et al .
Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with antiphospholipid antibodies.
BMJ.
1997;
314
253-257
-
47
Balasch J, Carmona F, Lopez-Soto A. et al .
Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome.
Hum Reprod.
1993;
8
2234-2239
-
48
Farquharson R G, Quenby S, Greaves M.
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.
Obstet Gynecol.
2002;
100
408-413
-
49
Branch D W, Peaceman A M, Druzin M. et al .
A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group.
Am J Obstet Gynecol.
2000;
182
122-127
-
50
Triolo G, Ferrante A, Ciccia F. et al .
Randomized study of subcutaneous low molecular weight heparin plus aspirin versus intravenous immunoglobulin in the treatment of recurrent fetal loss associated with antiphospholipid antibodies.
Arthritis Rheum.
2003;
48
728-731
-
51
Ginsberg J S, Hirsh J.
Use of antithrombotic agents during pregnancy.
Chest.
1998;
114 (5 Suppl)
524-530
-
52
Balasch J, Cervera R.
Reflections on the management of reproductive failure in the antiphospholipid syndrome - the clinician’s perspective.
Lupus.
2002;
11
467-477
-
53
Bazzan M, Donvito V.
Low-molecular-weight heparin during pregnancy.
Thromb Res.
2001;
101
175-186
-
54
Warkentin T E, Levine M N, Hirsh J. et al .
Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin.
N Engl J Med.
1995;
332
1330-1335
Priv.-Doz. Dr. C. Specker
Klinik für Rheumatologie & Klinische Immunologie, Katholisches Krankenhaus St. Josef. Zentrum für Innere Medizin der Kliniken Essen Süd
Propsteistraße 2
45239 Essen
Email: specker@rheumanet.org
